ライフサイエンスコーパス: cardiovascular events

1 s 8 [0-83], P<0.0001; similar for hard/total cardiovascular events).

2 raphy/computed tomography in vivo and future cardiovascular events.

3 tabolic activity predicts risk of subsequent cardiovascular events.

4 with significantly lower mortality and fewer cardiovascular events.

5 d 6 months were at the lowest risk of future cardiovascular events.

6 ne particle (PM2.5) pollution triggers acute cardiovascular events.

7 Secondary outcomes included major adverse cardiovascular events.

8 d discrimination index, especially for total cardiovascular events.

9 s infections, malignancies, or major adverse cardiovascular events.

10 of medication, and in-hospital and long-term cardiovascular events.

11 signed to improve lipid profiles and prevent cardiovascular events.

12 superior to clopidogrel for the reduction of cardiovascular events.

13 was associated with a >30% increased risk of cardiovascular events.

14 activity are associated with a lower risk of cardiovascular events.

15 use in all-cause mortality and major adverse cardiovascular events.

16 d intolerance to statins have a high risk of cardiovascular events.

17 rs, dual antiplatelet therapy, and long-term cardiovascular events.

18 ears; 58% women) who experienced 13821 major cardiovascular events.

19 ole in the pathogenesis of platelet-mediated cardiovascular events.

20 Odds ratio (OR) for major cardiovascular events.

21 Magmaris will result in reductions in major cardiovascular events.

22 and that PCTP expression is correlated with cardiovascular events.

23 al stiffness is an important risk factor for cardiovascular events.

24 ignificant coronary artery disease (CAD) and cardiovascular events.

25 these agents neither increased nor decreased cardiovascular events.

26 FR, and angiographic CAD severity on adverse cardiovascular events.

27 tion and treatment gaps increase the risk of cardiovascular events.

28 bo did not reduce the risk of major ischemic cardiovascular events.

29 o improve adherence may significantly reduce cardiovascular events.

30 the only independent factors associated with cardiovascular events.

31 ol (LDL-C) predicts both cerebrovascular and cardiovascular events.

32 er-intensity statins in adults without prior cardiovascular events.

33 luated aspirin for the primary prevention of cardiovascular events.

34 therosclerosis, coronary artery disease, and cardiovascular events.

35 as independent predictors of device-oriented cardiovascular events.

36 ved to be beneficial in preventing recurrent cardiovascular events.

37 atients with type 2 diabetes at high risk of cardiovascular events.

38 rial inflammation and the risk of subsequent cardiovascular events.

39 w-density lipoprotein cholesterol (LDL-C) on cardiovascular events.

40 urn could lead to reduced risk of downstream cardiovascular events.

41 in RA restores autonomic balance and reduces cardiovascular events.

42 ctor 15 identify patients at highest risk of cardiovascular events.

43 rgine with respect to the incidence of major cardiovascular events.

44 ements related to the prevention of clinical cardiovascular events.

45 g a perilous concurrence of risk factors for cardiovascular events.

46 0.78 mmol per liter) and reduced the risk of cardiovascular events.

47 t is likely to be recovered by prevention of cardiovascular events.

48 infarction, stroke, heart failure, and major cardiovascular events.

49 d cohort for risk prediction of coronary and cardiovascular events.

50 t could modulate the risk of atherosclerotic cardiovascular events.

51 %) hard cardiovascular, and 241 (7.3%) total cardiovascular events.

52 a higher frequency of diabetes mellitus and cardiovascular events.

53 (HR 0.53 [95% CI 0.40-0.71]), major adverse cardiovascular events (0.78 [0.69-0.87]), and hospital e

54 d high rates of hard coronary and hard/total cardiovascular events (10-year risk: 12.0%, 13.5%, and 3

55 es, 82 and 94 diabetes mellitus, 114 and 129 cardiovascular events, 119 and 147 non-AIDS malignancies

56 , 0.57; 95% CI, 0.50-0.65) and major adverse cardiovascular events (2.31 versus 3.45 events per 100 p

57 outcomes included in-hospital major adverse cardiovascular events, 30-day mortality, and 1-year mort

58 ave lower rates of in-hospital major adverse cardiovascular events, 30-day mortality, and 1-year mort

59 The primary outcome was major cardiovascular events (a composite of death, myocardial

60 dently associated with a 24% greater risk of cardiovascular events (adjusted hazard ratio [aHR], 1.24

61 zetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome.

62 However, current trends in cardiovascular events after kidney transplantation are p

63 anada, to determine whether the incidence of cardiovascular events after kidney transplantation has c

64 ial disease (PAD) have high rates of adverse cardiovascular events after percutaneous coronary interv

65 ng stroke after PVI, and explore the risk of cardiovascular events after PVI in patients with and wit

66 , when added to simvastatin therapy, reduces cardiovascular events after recent acute coronary syndro

67 the hazard ratio for all-cause mortality and cardiovascular events against the mean on-treatment SBP

68 the risk for the composite of major adverse cardiovascular events among the groups was similar.

69 of significant absolute increases of 1.2% in cardiovascular events and 0.4% in mortality with torcetr

70 Those with interval cardiovascular events and a dilated LV (increased LV end

71 es that nowadays patients more often survive cardiovascular events and a major number dies from cance

72 pared with <140 mm Hg reduced rates of major cardiovascular events and all-cause death without eviden

73 of the J curve was present, with a nadir for cardiovascular events and all-cause mortality just below

74 ent SBP levels are associated with increased cardiovascular events and all-cause mortality.

75 associated with a higher risk of subsequent cardiovascular events and bleeding.

76 ted with reduced mortality and incidences of cardiovascular events and cancer in obese individuals.

77 pproximately 2-fold increased risk of future cardiovascular events and cardiovascular death.

78 ssociations between adjudicated hospitalized cardiovascular events and claims-based methods of defini

79 new insights into stratification of risk of cardiovascular events and death among patients with chro

80 ntly lower rates of fatal and nonfatal major cardiovascular events and death from any cause.

81 F had markedly increased risk for subsequent cardiovascular events and death, highlighting the import

82 nts had additive effects on the risk of both cardiovascular events and diabetes.

83 eported a reduction in 3-point major adverse cardiovascular events and HF hospitalization risk.

84 ization for heart failure, and major adverse cardiovascular events and higher risk of below-knee lowe

85 ult in a relative increase in death or major cardiovascular events and may reflect improvements in st

86 essential hypertension, the excess risk for cardiovascular events and mortality was limited to patie

87 ified by cardiac imaging, is associated with cardiovascular events and predisposes to the development

88 cy is associated with decreased incidence of cardiovascular events and VTE.

89 SYNTAX scores predict higher rates of major cardiovascular events and were associated with more favo

90 respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, and all-cause death), and EF chan

91 association between on-treatment SBP levels, cardiovascular events, and all-cause mortality in patien

92 iabetes or type 2 diabetes], hyperlipidemia, cardiovascular events, and chronic kidney disease) (mean

93 determine the incidences of hepatic events, cardiovascular events, and death in CHB patients with or

94 of CHB patients in terms of hepatic events, cardiovascular events, and death remains unknown.

95 tion between baseline CPC/EPC levels, future cardiovascular events, and death.

96 ween AKI and cardiovascular mortality, major cardiovascular events, and disease-specific events: cong

97 D increased the risk of death, major adverse cardiovascular events, and major bleeding but did not af

98 e potassium concentrations with arrhythmias, cardiovascular events, and mortality.

99 reported all-cause mortality, major adverse cardiovascular events, and other outcomes of interest.

100 Patients with PAD are at high risk of cardiovascular events, and PCSK9 inhibition with evolocu

101 or posttransplant metabolic syndrome (PTMS), cardiovascular events, and renal insufficiency.

102 on is critical for the reduction of repeated cardiovascular events, and the control of cardiovascular

103 Hard coronary and cardiovascular events, and total cardiovascular events i

104 Cardiovascular events are associated with significant mo

105 y have a similar crude rate of major adverse cardiovascular events as those with type 1 myocardial in

106 me (ACS), the risk of recurrent coronary and cardiovascular events associated with FH might be mitiga

107 sation, and associated risk of major adverse cardiovascular events at 1 year.

108 fts with regard to mortality or the rates of cardiovascular events at 5 years of follow-up.

109 The rate of major adverse cardiovascular events at 5 years was 31.0% in the off-pu

110 ovides moderately strong evidence of reduced cardiovascular events at the expense of increased bleedi

111 ions with TFA restrictions experienced fewer cardiovascular events, beyond temporal trends, compared

112 /=50 years of age with >/=2 risk factors for cardiovascular events but with no prior cardiovascular e

113 sured with ultrasound correlates with future cardiovascular events, but conventional ultrasound imagi

114 ose did not reduce the risk of major adverse cardiovascular events, but did reduce the incidence of d

115 sis are crucially involved in development of cardiovascular events, but little is known about the inf

116 ; 95% CI, 0.89-1.37) and individual risks of cardiovascular events, but the risk of sternal wound inf

117 t disease by 27% (P=0.002) and major adverse cardiovascular events by 25% (P=0.004) consistently amon

118 t disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during the initia

119 we investigated the effect of evolocumab on cardiovascular events by diabetes status at baseline, de

120 bute to the clinically observed reduction in cardiovascular events by evaluating its effect on inflam

121 Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotei

122 ARRs of major cardiovascular events by statin therapy can be accuratel

123 Many assume that the reduction in cardiovascular events can be attributed to the anti-infl

124 were cardiovascular mortality, major adverse cardiovascular events (cardiovascular mortality, myocard

125 s class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all

126 cts of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality, and all

127 e did not significantly reduce major adverse cardiovascular events compared with asprin alone, but re

128 neither increased nor decreased the risk of cardiovascular events compared with placebo in patients

129 use associated with increased 30-day adverse cardiovascular events compared with the lowest tertile.

130 frequently displayed target organ damage and cardiovascular events compared with those without PA, in

131 owed until 31 December 2015 for incidence of cardiovascular events (composite of myocardial infarctio

132 9 (PCSK9) has been shown to be predictive of cardiovascular events (CVEs) in patients who are at high

133 y (32.2%) patients experienced intrahospital cardiovascular events (CVEs) including 281 (23.8%) with

134 prospectively followed for the occurrence of cardiovascular events (death, heart failure, hospitaliza

135 ation for heart failure event, major adverse cardiovascular events (defined as all-cause mortality, n

136 use and a composite outcome of major adverse cardiovascular events, defined as death from any cause,

137 tients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glarg

138 ttack (TIA) are at increased risk for future cardiovascular events despite current preventive therapi

139 tic vascular disease remain at high risk for cardiovascular events despite effective statin-based tre

140 e population and improved treatment of acute cardiovascular events, despite the efficacy of many ther

141 ge, lower income, and an absence of previous cardiovascular events, diabetes, obesity, or alcohol use

142 tients with low SYNTAX scores (</=22), major cardiovascular events did not differ significantly betwe

143 ular disease, the incidence of major adverse cardiovascular events did not differ significantly betwe

144 summary, compared to TASC, the proportion of cardiovascular events did not markedly decrease over the

145 tudies have shown that the increased risk of cardiovascular events disappears after risk adjustment.

146 (Prevention of Cardiovascular Events [e.g., Death From Heart or Vascula

147 Secondary outcomes included major adverse cardiovascular events (eg, nonfatal myocardial infarctio

148 MF noted on CMR had a higher probability of cardiovascular events (event rate, 10 of 55 [18.2%] vs 0

149 8 (17%) patients, with the most common being cardiovascular events (four patients [4%]).

150 85% of the overall study population) averted cardiovascular events from a behavioural intervention ai

151 ues are associated with an increased risk of cardiovascular events, giving rise to the so-called J-cu

152 ents with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular

153 ; 95% confidence interval, 1.10 to 1.72) and cardiovascular events (hazard ratio, 1.23; 95% confidenc

154 ) was associated with a higher risk of major cardiovascular events (hazard ratio: 1.36, confidence in

155 ndependently associated with secondary major cardiovascular events (hazard ratio=2.28; 95% confidence

156 ), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular ac

157 the study medications) a lower risk of major cardiovascular events; however, they also had lower isch

158 Patients with SVRs also had a lower risk of cardiovascular events (HR, 0.42; 95% CI, 0.25-0.69; P =

159 nce interval [CI], 2.14-2.22), major adverse cardiovascular events (HR, 1.37; 95% CI, 1.34-1.41), isc

160 [CI]:1.26 to 1.56; p <0.001), major adverse cardiovascular events (HR: 1.29; 95% CI: 1.16 to 1.43; p

161 s associated with a significant reduction in cardiovascular events in 18144 patients after acute coro

162 eing tested as a method to prevent recurrent cardiovascular events in a randomized trial of 10 065 po

163 ndependently associated with secondary major cardiovascular events in a severely atherosclerotic popu

164 T, and growth-differentiation factor 15 with cardiovascular events in ACHD.

165 ctor of future major adverse atherosclerotic cardiovascular events in asymptomatic individuals.

166 ether acarbose could reduce the frequency of cardiovascular events in Chinese patients with establish

167 poprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to inc

168 in (hs-CRP) is independently associated with cardiovascular events in coronary artery disease (CAD) p

169 lude that TMAO concentration associates with cardiovascular events in hemodialysis patients but the e

170 r the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction

171 e that plasma MGO levels are associated with cardiovascular events in individuals with type 1 diabete

172 In comparison with adjudicated cardiovascular events in MESA, the concordance rates for

173 Considering the high risk for major adverse cardiovascular events in patients receiving hemodialysis

174 n aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral is

175 We aimed to investigate the risk of incident cardiovascular events in patients with primary aldostero

176 (Prevention of Cardiovascular Events in Patients with Prior Heart Attac

177 The PEGASUS-TIMI (Prevention of Cardiovascular Events in Patients with Prior Heart Attac

178 14,355) from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attac

179 alongside the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attac

180 orapaxar) and PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attac

181 osis factor-alpha blockade appears to reduce cardiovascular events in patients with severe psoriasis.

182 Evolocumab was equally effective in reducing cardiovascular events in patients with stable atheroscle

183 tries have shown reductions in major adverse cardiovascular events in psoriasis patients and rheumato

184 haemodialysis (HD) have an increased risk of cardiovascular events in the first year after starting H

185 g the association between alcohol intake and cardiovascular events in the following hours and days.

186 uced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Card

187 bitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial.

188 ation for the primary prevention of clinical cardiovascular events in the general population have not

189 onocyte-derived macrophages, predicts future cardiovascular events in the general population.

190 logy, could help to explain residual risk of cardiovascular events in the general population.

191 There were 2 adverse cardiovascular events in the metoprolol group and none i

192 There were modestly more cardiovascular events in the MMF/SRL group.

193 sociation between atopic dermatitis (AD) and cardiovascular events in the Nurses' Health Study 2, a c

194 had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk

195 as an independent predictor of major adverse cardiovascular events in those with type 2 myocardial in

196 sociation between exogenous testosterone and cardiovascular events, in men aged 18 years or older gen

197 Cardiovascular events including myocardial infarction, i

198 a primary endpoint of a composite of adverse cardiovascular events including myocardial infarction, s

199 oronary and cardiovascular events, and total cardiovascular events including revascularization, as we

200 HF had markedly increased risk of subsequent cardiovascular events, including a 27-fold increase (P<0

201 ) for a composite end point of major adverse cardiovascular events, including cardiovascular death an

202 Major cardiovascular events, including nonfatal myocardial inf

203 nal risk factors and medications) to predict cardiovascular events increased the C statistic from 0.6

204 We also noticed that the risk for cardiovascular events increased with increasing number o

205 dimensional speckle tracking predicts future cardiovascular events independent of conventional risk f

206 d with higher mortality and a higher rate of cardiovascular events independent of traditional cardiov

207 reduced regenerative capacity contribute to cardiovascular events, independent of conventional risk

208 ipid and lipoprotein levels, and the risk of cardiovascular events involving 102837 participants from

209 onation, the risk of all-cause mortality and cardiovascular events is no higher than in healthy nondo

210 Whether it prevents cardiovascular events is uncertain.

211 elial dysfunction, a major predictor of late cardiovascular events, is linked to the severity of obst

212 owever, an abnormal FT was more specific for cardiovascular events, leading to overall similarly mode

213 identified those patients at highest risk of cardiovascular events (log-rank P<0.0001).

214 control (<120 mm Hg) had fewer major adverse cardiovascular events (MACE) and deaths but higher rates

215 formed multivariable model for major adverse cardiovascular events (MACE) and determined the continuo

216 We prospectively studied major adverse cardiovascular events (MACE) at 2 years in 607 patients

217 rotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) has been observed in statin

218 t is associated with increased major adverse cardiovascular events (MACE) in the setting of acute cor

219 Major adverse cardiovascular events (MACE) were defined as the primary

220 of a family history of AF with major adverse cardiovascular events (MACE).

221 incident type 1 and T2MI, and major adverse cardiovascular events (MACE, a composite of all-cause de

222 ion and target vessel failure (major adverse cardiovascular events [MACE]).

223 Cardiovascular (major adverse cardiovascular events [MACE], cardiovascular mortality,

224 ar AF were recruited and rates of thrombotic/cardiovascular events, major bleeding and mortality were

225 he efficacy of NHE inhibitors on the risk of cardiovascular events may be enhanced when heart failure

226 omes included 1-year composite major adverse cardiovascular events, moderate to severe bleeding, and

227 ale (ESS) scores, blood pressure, mortality, cardiovascular events, motor vehicle crashes, quality of

228 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted hazard rat

229 re reductions on relative risk (RR) of major cardiovascular events (myocardial infarction, stroke, he

230 o compare all-cause mortality, major adverse cardiovascular events, myocardial infarction (MI), or ta

231 (n = 1094; 21%), and those with preexisting cardiovascular events (n = 1620; 35%).

232 .3 pmol/L) was most strongly associated with cardiovascular events (n=165, adjusted hazard ratio, 9.0

233 ed diabetes mellitus, chronic renal failure, cardiovascular events, NLR-NAR cancer, bone events, and

234 During a median follow-up of 3.3 years, cardiovascular events occurred in 1014 patients (7.3%),

235 nd the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in t

236 d the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients,

237 However, serious cardiovascular events occurred in 22.8% of aspirin users

238 Major cardiovascular events occurred in 57 patients (2.5%) who

239 No major adverse cardiovascular events occurred in either group.

240 in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofa

241 g a median of 3.0 years of follow-up, 62 690 cardiovascular events occurred.

242 Despite finding no significant reduction in cardiovascular events on average, it is possible that so

243 re no deaths and four positively adjudicated cardiovascular events, one (3%) among patients on aphere

244 increase, respectively) but not with risk of cardiovascular events or graft failure.

245 on between sodium intake and cardiovascular (cardiovascular events or mortality) and renal (end-stage

246 rval [CI], 0.55-1.12; P=0.19), major adverse cardiovascular events (OR, 0.73, CI, 0.51-1.05; P=0.09),

247 ding attenuated nonsignificant risk of major cardiovascular events (OR, 0.985 [95% CI, 0.955-1.015]).

248 waist circumference), cases of T2D, cases of cardiovascular events, or risk markers thereof.

249 e of the composite outcome or death-censored cardiovascular events over time (P = 0.41 and 0.92, resp

250 profile (and numerically the lowest rate of cardiovascular events) over a 6-year period compared wit

251 linical parameters as well as biomarkers for cardiovascular events (P <0.001).

252 5), history of smoking (P = 0.01), and prior cardiovascular events (P = 0.0004).

253 d risk of cardiovascular mortality and major cardiovascular events, particularly heart failure and ac

254 rum calcium levels, may increase the risk of cardiovascular events, particularly myocardial infarctio

255 tatins under both guidelines experienced 9.6 cardiovascular events per 1000 patient-years, those indi

256 on between the HMGCR score and risk of major cardiovascular events per unit change in levels of LDL-C

257 incidence, and (3) identify risk factors for cardiovascular events post-liver transplantation.

258 sease were the most consistent predictors of cardiovascular events posttransplant (significant in 8/2

259 rs-has been reported to decrease the risk of cardiovascular events primarily by reducing the risk of

260 ignificant step-up increase in major adverse cardiovascular events rate was observed across the 3 FFR

261 L-C (and other lipoproteins) and the risk of cardiovascular events related to variants in the CETP ge

262 Cardiovascular events represent a major source of morbid

263 d risk of cardiovascular mortality and major cardiovascular events, respectively ([RR 1.86; 95% confi

264 hs, 93 and 44 patients developed hepatic and cardiovascular events, respectively; 70 patients died.

265 +)CD133(+): low versus high levels predicted cardiovascular events, restenosis after endovascular int

266 cant associations were found between vWF and cardiovascular events, stroke, mortality and bleeding.

267 ypertension, atherosclerosis, and associated cardiovascular events such as myocardial infarction, str

268 eased plasma TMAO concentrations and adverse cardiovascular events, such as myocardial infarction, st

269 cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical bene

270 erence in all-cause mortality, major adverse cardiovascular events, target vessel revascularization,

271 on (PMO) is more predictive of major adverse cardiovascular events than myocardial infarct (MI) size.

272 clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin.

273 ho discontinued aspirin had a higher rate of cardiovascular events than those who continued (multivar

274 eated with canagliflozin had a lower risk of cardiovascular events than those who received placebo bu

275 yndrome had higher cumulative probability of cardiovascular events than those without (8.0% versus 2.

276 and apoB levels and a corresponding risk of cardiovascular events that was proportional to the atten

277 s 0.55 [0.34-0.90]), while for major adverse cardiovascular events the HR in the group with cardiovas

278 baseline and 6 months, and the incidence of cardiovascular events through 24 months (P<0.001 for eac

279 Examining cumulative cardiovascular events (total burden of disease) gives a

280 o identify surgical subtypes associated with cardiovascular events using a large administrative datab

281 es Study (DPPOS, n=1018; 1996-2001), and for cardiovascular events using data from the Action for Hea

282 enicline 11.9%, placebo 11.3%; major adverse cardiovascular events: varenicline 4.0%, placebo 4.6%).

283 activity, the adjusted hazard ratio (HR) for cardiovascular events was 0.52 (95% confidence interval

284 The incidence of cardiovascular events was higher in patients with primar

285 fected sisters, whereas an increased risk of cardiovascular events was observed in brothers only.

286 rated fatty acid supplementation on clinical cardiovascular events, we update prior recommendations f

287 on coronary heart disease and major adverse cardiovascular events were assessed over the 4.9-year ra

288 rospectively followed SCAD cohort, long-term cardiovascular events were common.

289 ed as stenosis greater than or equal to 50%; cardiovascular events were defined as a composite of car

290 Trends in deaths and cardiovascular events were estimated with Cox regression

291 The associations with cardiovascular events were externally validated in 18953

292 Cardiovascular events were identified with the Swedish i

293 with mid/high SYNTAX scores, however, major cardiovascular events were lower after revascularization

294 lar risk, but without diabetes, the rates of cardiovascular events were lower among those who were as

295 Incident cardiovascular events were observed among 70 patients (2

296 ding 44,989 participants, in whom 2496 major cardiovascular events were recorded during a mean 3.8 ye

297 The rates of in-hospital major adverse cardiovascular events were significantly lower in patien

298 study progression of subclinical disease to cardiovascular events where participants were initially

299 provided evidence of benefit in reduction of cardiovascular events with these agents.

300 igh school, and college and above], previous cardiovascular events [yes or no], current smoker [yes o